What question did this study set out to answer?

This research aims to improve drug-target interaction (DTI) predictions by addressing the challenges of ligand and protein novelty.

April 25, 2026BMC BioinformaticsOpen Access

Protein and ligand novelty in drug–target interaction prediction: a dual-encoder fusion strategy for more interpretable and generalizable modeling

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial evaluates a dual-encoder model for drug-target interactions, suggesting enhanced reliability and interpretability.

This research aims to improve drug-target interaction (DTI) predictions by addressing the challenges of ligand and protein novelty.
Developed a dual-encoder fusion framework using pretrained ESM protein embeddings and complementary ligand representations.
Implemented a novelty-aware evaluation protocol and gradient-based interpretability analysis.
Conducted experiments on the BindingDB dataset to assess model performance under different novelty conditions.
Ligand novelty caused limited performance degradation with F1 scores of 0.84-0.87 and AUC values of 0.87-0.89.
Protein novelty was identified as a significant performance bottleneck, particularly under cold-protein and double-cold settings.
The fusion model achieved an AUC of 0.90 in the warm setting and consistent values (0.60-0.64) during external validation on independent datasets.

Abou-Abbas et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark